Clinical Trial Update: Efficacy and Safety of DHEA for Myotonic Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

An update on phase 2/3 trials evaluating the efficacy and safety of dehydroepiandrosterone (DHEA) for myotonic dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy

Drugs mentioned

• DHEA (dehydroepiandrosterone)

Snippet

Sponsor: University of Versailles | Conditions: Myotonic Dystrophy | Phase 2, Phase 3 | Status: COMPLETED